Neuromuscular electrical stimulation acutely mobilizes endothelial progenitor cells in critically ill patients with sepsis

Christos Stefanou¹, Eleftherios Karatzanos¹, Georgios Mitsiou¹, Katerina Psarra², Epameinondas Angelopoulos¹, Stavros Dimopoulos¹,³, Vasiliki Gerovasili¹, Efthathios Boviatis⁴, Christina Routsi¹ and Serafeim Nanas¹*

Abstract

Background: Endothelial progenitor cells (EPCs) have been suggested to constitute a restoration index of the disturbed endothelium in ICU patients. Neuromuscular electric stimulation (NMES) is increasingly employed in ICU to prevent comorbidities such as ICU-acquired weakness, which is related to endothelial dysfunction. The role of NMES to mobilize EPCs has not been investigated yet. The purpose of this study was to explore the NMES-induced effects on mobilization of EPCs in septic ICU patients.

Methods: Thirty-two septic mechanically ventilated patients (mean ± SD, age 58 ± 14 years) were randomized to one of the two 30-min NMES protocols of different characteristics: a high-frequency (75 Hz, 6 s on–21 s off) or a medium-frequency (45 Hz, 5 s on–12 s off) protocol both applied at maximally tolerated intensity. Blood was sampled before and immediately after the NMES sessions. Different EPCs subpopulations were quantified by cytometry markers CD34⁺/CD133⁺/CD45⁻, CD34⁺/CD133⁺/CD45⁻/VEGFR₂⁺ and CD34⁺/CD45⁻/VEGFR₂⁺.

Results: Overall, CD34⁺/CD133⁺/CD45⁻ EPCs increased from 13.5 ± 10.2 to 20.8 ± 16.9 and CD34⁺/CD133⁺/CD45⁻/VEGFR₂⁺ EPCs from 3.8 ± 5.2 to 6.4 ± 8.5 cells/10⁶ enucleated cells (mean ± SD, p < 0.05). CD34⁺/CD45⁻/VEGFR₂⁺ EPCs also increased from 16.5 ± 14.5 to 23.8 ± 19.2 cells/10⁶ enucleated cells (mean ± SD, p < 0.05). EPCs mobilization was not affected by NMES protocol and sepsis severity (p > 0.05), while it was related to corticosteroids administration (p < 0.05).

Conclusions: NMES acutely mobilized endothelial progenitor cells, measures of the endothelial restoration potential, in septic ICU patients.

Keywords: Electrical muscle stimulation, NMES, EPC, Early rehabilitation, Critical illness, Acute effect

Background

Endothelium, a key regulator of homeostasis, is disturbed in ICU patients and is associated with multi-organ failure [1]. The relation of endothelial function with endothelial progenitor cells (EPCs) has been shown for different groups, such as healthy populations with or without cardiovascular risk factors [2, 3], patients with coronary artery disease [4] and chronic heart failure (CHF) [5].

Accumulating evidence has suggested multiple roles for EPCs in endothelial physiology, such as neovascularization, endothelial repair and restoration of endothelial function [6]. EPCs are bone marrow-derived precursors of endothelial cells with potential capacity to proliferate, migrate, differentiate or exert paracrine action.

Neuromuscular electrical stimulation (NMES), suggested as an alternative form of exercise in critically ill patients, seems to be potentially beneficial in preserving muscle strength and muscle mass as well as in reducing the duration of weaning and the incidence of ICU-acquired weakness [7–10]. Acutely applied NMES in ICU also induced systemic beneficial effects
on the microcirculation, which is closely related to endothelial function [11]. Furthermore, increased EPCs levels have been observed in response to acute bouts of exercise in healthy populations [12–14] and patients with CHF [5]. However, the role of acute NMES in raising EPCs counts in ICU patients has not been investigated yet.

It was hypothesized that an NMES session would increase counts of EPCs in severe ICU patients. The main purpose of this study was to explore the role of acutely applied NMES on mobilizing progenitor endothelial cells in septic critically ill patients.

Methods

Patients

Patients admitted to the multi-disciplinary ICUs of Evangelismos Athens General Hospital were considered for inclusion. Inclusion criteria were the presence of sepsis for >72 h and mechanical ventilation. Determination of sepsis was based on criteria, as previously described [15]. Exclusion criteria were age <18 and >80 years, pregnancy, moribund, body mass index (BMI) >35 kg/m², severe edema (deep indentation when pressing finger into skin, requiring >30 s to rebound), ICU-acquired weakness, ICU length of stay ≥20 days prior to study enrollment, history of neuromuscular disease at admission, implanted pacemaker/defibrillator, technical restrictions not allowing NMES application (e.g., bone fractures or skin lesions), thromboembolic disease, continuous hemodialysis, ongoing transfusion, and chemotherapy or other forms of myelotoxicity.

Study design

This was a prospective randomized study. Eligible patients were randomized to one session of NMES using one of the two protocols with different characteristics. Blood samples were collected before and within 5 min after the session for flow cytometry analyses. Mean arterial blood pressure, heart rate, respiratory rate and ECG were monitored during the session. Lactate and creatine phosphokinase were also recorded before and after the session for flow cytometry analyses. For evaluation of EPCs, blood samples were drawn from an antecubital or existing central vein; the first 3 ml were discarded. Venous blood was collected in acid citrate dextrose tubes of 5 ml capacity 5 min before and at the end of the NMES sessions and was processed within 3 h of collection. Blood samples were kept at 4 °C throughout the procedure. Whole peripheral blood samples were analyzed by flow cytometry [17]. During the procedure, fresh samples were centrifuged at 700 g for 20 min with no brake. The upper phase (plasma) was gently removed into a separate tube and stored in 0.25 ml aliquots. The lower phase containing the blood cells was resuspended using 10 ml of cold 1 × PBS containing 0.5 % (w/v) BSA and 1.5 mM EDTA and centrifuged at 700 g for 20 min with no brake for a second time. The upper phase was removed and discarded; the cell pellet was resuspended, and 2.5 ml was transferred into a separate tube and kept on ice. Concomitantly, 500 μl of samples was also transferred into one isotype control and three sample tubes and the appropriate antibodies were added: Then, 9 ml of ACK lysing buffer was added (to lyse red blood cells), vortexed briefly and incubated at room temperature (18–25 °C) for 3 min. It was washed twice with 9 ml of cold regular 1 × PBS and centrifuged at 250 g at 4 °C with brake for 5 min. The cell pellet was resuspended in 500 μl

Application of neuromuscular electrical stimulation

For NMES application (Rehab 4 Pro, CEFAR Medical AB, Malmö, Sweden), rectangular electrodes (90 × 50 mm) were placed on the motor points of vastus lateralis, vastus medialis and peroneus longus of both lower extremities, after appropriate skin preparation. During the session, the angle of the patients’ knee joint was approximately 40° (0° corresponding to full knee extension). NMES sessions lasted for 40 min including 10 min for warm-up and recovery (10 Hz, 400 μs).

Patients were assigned to a high-frequency (HF) or a medium-frequency protocol (MF), as previously described [16]. In short, both protocols employed symmetric, biphasic, trapezoid pulses, with 400-μs pulse duration and 1.5/0.8-s ramp-up/ramp-down duration, respectively. HF consisted of 75 Hz pulses with 6 s on–21 s off. MF consisted of 45 Hz pulses with 5 s on–12 s off. Current intensity, optimally aiming at full muscle contraction, was continuously increased during the sessions, to prevent fatigue. In sedated patients, starting intensity was set at 60–80 % of that resulting in maximal response and increased by 10 % every 3 min up to 100 %. In non-sedated patients, intensity was initially set to the maximum tolerated level and was increased by 10 % (or less in case of discomfort) every 3 min throughout the session.

Blood sampling and flow cytometry analyses

For evaluation of EPCs, blood samples were drawn from an antecubital or existing central vein; the first 3 ml were discarded. Venous blood was collected in acid citrate dextrose tubes of 5 ml capacity 5 min before and at the end of the NMES sessions and was processed within 3 h of collection. Blood samples were kept at 4 °C throughout the procedure. Whole peripheral blood samples were analyzed by flow cytometry [17]. During the procedure, fresh samples were centrifuged at 700 g for 20 min with no brake. The upper phase (plasma) was gently removed into a separate tube and stored in 0.25 ml aliquots. The lower phase containing the blood cells was resuspended using 10 ml of cold 1 × PBS containing 0.5 % (w/v) BSA and 1.5 mM EDTA and centrifuged at 700 g for 20 min with no brake for a second time. The upper phase was removed and discarded; the cell pellet was resuspended, and 2.5 ml was transferred into a separate tube and kept on ice. Concomitantly, 500 μl of samples was also transferred into one isotype control and three sample tubes and the appropriate antibodies were added: Then, 9 ml of ACK lysing buffer was added (to lyse red blood cells), vortexed briefly and incubated at room temperature (18–25 °C) for 3 min. It was washed twice with 9 ml of cold regular 1 × PBS and centrifuged at 250 g at 4 °C with brake for 5 min. The cell pellet was resuspended in 500 μl
of 1 x PBS, and the samples were filtered through 40-μm cell strainer into 5-ml BD Falcon tubes. The tubes were held at 4 °C (or on ice) in the dark before acquisition on the flow cytometer. Flow cytometry was performed in the Flow Cytometry Core Laboratory with BD FACS can II (Becton–Dickinson) flow cytometer. An acquisition gate was established that included mononuclear cells but excluded most granulocytes and debris; 10^6 mononuclear events were routinely collected to determine this population. Finally, Boolean analysis using combination of specific surface markers was applied. Different EPCs subpopulations were quantified by cytometry markers CD34^+ /CD133^+ /CD45^- and CD34^+ /CD133^- /VEGFR2^+ and CD34^+ /CD45^- /VEGFR2^+ [17, 18] (Fig. 1).

Statistical analyses
Continuous variables are reported as mean ± standard deviation (SD). Normality of distribution was checked with Kolmogorov–Smirnov test. Student's paired t test or Wilcoxon signed-rank test (in case of not normal distribution) was employed for within-group differences. Differences between subgroups were assessed with factorial analysis of variance (ANOVA) 2 x 2 (time x group). Effect size was calculated as mean of the difference/SD of the difference. Statistical significance was set to p < 0.05. Statistical analyses were performed with IBM SPSS 20.

Results
Thirty-two patients were included. Demographic and clinical characteristics are presented in Table 1. No difference was observed in these characteristics between subgroups (p > 0.05) in terms of NMES protocols, steroids administration and sepsis severity. Concerning sepsis severity, SOFA score was higher in the higher SOFA group (p = 0.04) (data not shown). NMES sessions took place on 7.6 ± 0.8 days from admission.

In the whole group, NMES increased CD34^+ /CD133^+ /CD45^- EPCs from 13.5 ± 10.2 to 20.8 ± 16.9 cells/10^6 enucleated cells (+54 %, corresponding to effect size: 0.46, p = 0.02) (Figs. 2, 3). In regard to subgroup comparisons (Table 2), this EPCs population increased in MF (p = 0.04), but not in HF (p = 0.18). No between-protocol differences were observed (p = 0.60). Baseline number was lower in MF than HF (p = 0.03). CD34^+ /CD133^- /CD45^- EPCs count also increased in the nonsteroids (p < 0.01), but not in the steroids group (p = 0.46). A significant between-group difference was observed (p = 0.02), while no difference was found in baseline number (p = 0.21). Finally, lower SOFA score (p = 0.04) and higher SOFA score patients (p = 0.07) increased CD34^+ /CD133^- /CD45^- EPCs number, with no between-group difference either in total (p = 0.88) or at baseline (p = 0.95).

Similar results were observed for CD34^+ /CD133^- /CD45^- /VEGFR2^+ EPCs, which were increased in the whole cohort from 3.8 ± 5.2 to 6.4 ± 8.5 cells/10^6 enucleated cells (+68 %, corresponding to effect size: 0.33, p = 0.04) (Figs. 2, 3). In relation to subgroup comparisons (Table 2), these were tended to increase in MF (p = 0.06), but not in HF (p = 0.31), while no between-protocol difference was found (p = 0.91). CD34^+ /CD133^- /CD45^- /VEGFR2^+ EPCs count increased in the nonsteroids (p < 0.01), but not in the steroids group (p = 0.17); a significant between-group difference was observed (p < 0.01). Finally, higher SOFA score (p = 0.04) but not lower SOFA score patients (p = 0.50) increased

Fig. 1 Representative dot plot FACS analysis for endothelial progenitor cells determination. Boolean analysis was performed. In all samples, the CD34 expression was dim
CD34+/CD133+/CD45− EPCs number, with no between-group difference (p = 0.43). In addition, no differences between subgroups at baseline were found for all comparisons employed (p > 0.05).

In relation to CD34+/CD45−/VEGFR2+ EPCs, the entire group increased number from 16.5 ± 14.5 to 23.8 ± 19.2 cells/10⁶ enucleated cells (+44 %, corresponding to effect size: 0.42, p < 0.01) (Figs. 2, 3). Its count did not change in HF (p = 0.13), while it increased in MF (p = 0.03). It was also increased in the nonsteroids (p < 0.01), but not in the steroids group (p = 0.84). Finally, higher SOFA score group (p = 0.01), but not lower SOFA patients (p < 0.01), increased CD34+/CD45−/VEGFR2+ EPCs number. No significant between-group difference was found in terms of NMES protocol (p = 0.20), steroid administration (p = 0.21) or sepsis severity (p = 0.82) (Table 2).

In the whole group during the NMES sessions, there were increases in heart rate (from 89 ± 20 to 92 ± 19 beats/min, p = 0.04) and respiratory rate (from 21 ± 6 to 22 ± 6 breaths/min, p = 0.03), while mean arterial pressure did not change (from 89 ± 11 to 92 ± 17 mmHg, p = 0.19). Increases were also observed in creatine phosphokinase (from 498 ± 961 to 526 ± 1011 IU/L, p < 0.01) and lactate (from 1.1 ± 0.4 to 1.4 ± 0.6 mmol/L, p < 0.01). No ECG and hemodynamic derangements occurred during the sessions.

**Discussion**

This study showed that a single NMES session increased counts of endothelial progenitor cells in critically ill patients with sepsis. To the best of our knowledge, this is

---

**Table 1 Demographic and clinical characteristics of patients included in the study**

| Age (years) | Gender (male/female) | APACHE II score on admission | SOFA score on admission | SOFA score on session day | Diagnostic category at admission | Comorbidities |
|-------------|----------------------|-----------------------------|-------------------------|---------------------------|---------------------------------|--------------|
| 58 ± 14     | 23/9                 | 21 ± 8                      | 7 ± 3                   | 7 ± 3                     | Post-surgery [n (%)] 12 (38 %)  | Cardiovascular disease [n (%)] 19 (59 %) |
|             |                      |                             |                         |                           | Respiratory failure [n (%)] 8 (25 %) | Respiratory disease [n (%)] 5 (16 %) |
|             |                      |                             |                         |                           | Cardiovascular failure [n (%)] 4 (12 %) | Hepatic disease [n (%)] 5 (16 %) |
|             |                      |                             |                         |                           | Trauma [n (%)] 3 (9 %) | Renal disease [n (%)] 5 (16 %) |
|             |                      |                             |                         |                           | Neurological [n (%)] 3 (9 %) | Diabetes mellitus [n (%)] 12 (38 %) |
|             |                      |                             |                         |                           | Other [n (%)] 2 (6 %) | Hematological/anticoagulated [n (%)] 6 (19 %) |
|             |                      |                             |                         |                           | Medication on session day | Corticosteroids [n (%)] 10 (31 %) |
|             |                      |                             |                         |                           | Antimicrobials [n (%)] 30 (94 %) | Noradrenaline [n (%)] 12 (38 %) |
|             |                      |                             |                         |                           | Sedatives [n (%)] 15 (47 %) |

* Values are expressed as mean ± SD

**Fig. 2** Change of the three EPCs subpopulations number (mean ± SD) before and after the NMES sessions. EPCs endothelial progenitor cells; asterisk significant difference compared to pre-NMES value (p < 0.05)
Fig. 3  Change of EPCs number before and after the NMES sessions for each of the 32 patients included. a CD34⁺/CD133⁺/CD45⁻ EPCs, b CD34⁺/CD133⁺/VEGFR₂⁺ EPCs, c CD34⁺/CD45⁻/VEGFR₂⁺ EPCs. EPCs endothelial progenitor cells
the first study to demonstrate NMES efficacy on mobilizing progenitor cells, an index of the endothelial restoration potential, in ICU patients.

Previous pilot studies, exploring the effects of short-term protocols employing NMES in combination with intermittent hypobaric hypoxia or exercise, have shown increased number of progenitor cells in healthy subjects and patients with traumatic brain injury [19, 20]; obviously, these studies are not feasible to compare with our study.

In ICU patients, NMES seems to prevent muscle weakness and improve muscle strength [8, 9] while it has also the potential to prevent muscle atrophy [7, 10, 21]. Acutely applied NMES can induce systemic beneficial effects on microcirculation, which is related to mechanisms of ICU-acquired weakness, including disturbances in macro- and microvascular function [22, 23]. Further evidence suggests that NMES can reduce ICU-acquired weakness incidence and duration of weaning, although this needs to be verified by large RCTs [9, 24]. From these points of view, NMES has been suggested as a form of exercise to mobilize and induce rehabilitative interventions to ICU patients [25]. There is also increasing interest in the NMES role concerning therapy of pressure ulcers [26] and prevention of deep vein thrombosis [22, 23].

Previous studies have also demonstrated increased levels of EPCs subpopulations or their migratory capacity in response to acute bouts of aerobic exercise in healthy populations and other critically ill patients, such as patients with CHF [5, 14]. These effects were attenuated in CHF [27]. Interestingly, recent data also suggested a beneficial effect of acute resistance training on improving EPCs counts and angiogenic factors in healthy subjects [13]. NMES, as applied in this study, may have more similarities to resistance exercise in that it stimulated isolated muscle groups.

Shear stress may be suggested as a triggering factor for EPCs release after a single NMES session. Shear stress-induced up-regulation and increased activity of endothelial nitric oxide synthase are related to increased nitric oxide production by endothelial cells [28], contributing to amplified number and activity of circulating EPCs [3]. NMES application on the calf muscles of healthy subjects and patients after total hip replacement surgery acutely increased popliteal blood flow and volume flow, reflecting increases in shear stress-induced vasodilatation [22, 23]. The importance of ischemic/hypoxic stimulus to increase EPCs count has been also implied in short-term studies enrolling patients with cardiovascular disease [29]. In a recent animal study, short-term NMES-induced ischemic training moderately increased EPCs [30]. EPCs have been also increased in response to acute exercise- and non-exercise-induced ischemic stimulus in patients with peripheral arterial occlusive disease and healthy participants, respectively [31]. NMES, mainly resulting in isometric contractions, has the potential to induce hypoxic stimuli, as suggested by alterations in microcirculation indices during NMES sessions in healthy populations [32] and ICU patients [16]. These mechanisms may relate to up-regulation of transcriptional factors, such as matrix metalloproteinases, stromal cell-derived factor 1 and vascular endothelial growth factor, which mediate processes to promote proliferative and migratory capacities of circulating EPCs [5, 13, 31]. The proposed mechanisms and mediating factors in relation to the different subpopulations of progenitor cells, as well as the time course of the changes, should be addressed in future studies exploring the effects of NMES in ICU patients.

Table 2 EPCs numbers (cells/million enucleated cells, mean ± SD) before and after NMES sessions for the subgroups in terms of NMES protocol, steroids administration and sepsis severity

| Subgroups                        | CD34+/CD133+/CD45+ EPCs | CD34+/CD133+/CD45+/VEGFR2+ EPCs | CD34+/CD45+/VEGFR2+ EPCs |
|----------------------------------|--------------------------|----------------------------------|--------------------------|
|                                  | Pre-                      | Post-                            | p*                      | Pre-                      | Post-                            | p* | p#                     |
| By NMES protocols                |                          |                                  |                         |                          |                                  |    |                       |
| HF                               | 18.0 ± 11.6               | 23.6 ± 18.1                      | 0.18 0.60               | 4.8 ± 46                  | 7.3 ± 94                        | 0.31 0.91               | 15.9 ± 15.6 | 18.6 ± 11.6 | 0.13 0.20 |
| MF                               | 10.1 ± 7.6                | 18.7 ± 16.1                      | 0.04                    | 2.9 ± 56                  | 5.8 ± 80                        | 0.06 0.91               | 17.0 ± 14.1 | 28.0 ± 23.0 | 0.03 0.96 |
| By steroids administration       |                          |                                  |                         |                          |                                  |    |                       |
| Steroids                         | 16.7 ± 8.8                | 14.2 ± 8.6                       | 0.46 0.02               | 5.5 ± 75                  | 2.6 ± 23                        | 0.13 <0.01            | 21.0 ± 19.3 | 22.5 ± 22.5 | 0.84 0.21 |
| Nonsteroids                      | 12.1 ± 10.6               | 23.8 ± 19.0                      | <0.01                   | 3.0 ± 3.7                 | 8.2 ± 98                        | <0.01 <0.01        | 145.0 ± 11.8 | 245.0 ± 18.1 | <0.01 <0.01 |
| By sepsis severity               |                          |                                  |                         |                          |                                  |    |                       |
| Lower SOFA score patients        | 13.4 ± 10.1               | 22.5 ± 20.9                      | 0.04 0.88               | 3.3 ± 3.7                 | 4.9 ± 7.7                       | 0.50 0.43             | 149.0 ± 15.6 | 21.4 ± 17.8 | 0.24 0.82 |
| Higher SOFA score patients       | 13.2 ± 9.6                | 21.4 ± 13.8                      | 0.07                    | 4.6 ± 6.4                 | 8.5 ± 94                        | 0.04                | 166.0 ± 13.1 | 24.7 ± 19.9 | 0.01 0.01 |

EPCs: endothelial progenitor cells; HF: high-frequency NMES protocol; MF: medium-frequency NMES protocol
*p value for within-group differences; # p value for between-group differences
An interesting finding was that patients on corticosteroids did not increase progenitor cells in contrast to patients not on steroids. Corticosteroids may affect EPCs mobilization and activity. Previous studies on EPCs mobilization and function employing patients on corticosteroids medication have provided similar [33, 34], neutral [35] or contrasting results [36, 37]. In the latter studies, this finding could be related to the fact that steroids administration had a stronger effect on interleukin 1 reduction and rheumatic disease remission—the main cause of progenitor cells suppression—than EPCs number per se [38]. In this study, no difference was detected between the two corticosteroids subgroups at baseline EPCs counts and that was also the case for SOFA and APACHE scores. Several confounding factors such as small sample size, severity of disease (not able to be reflected on conventional scales, such as SOFA score) and presence of inflammation may have interfered with these observations. Further research is necessary to explore the role of corticosteroids on mobilizing EPCs in response to NMES before reaching definite conclusions.

Both medium- and high-frequency protocols were found to similarly increase EPCs. Although MF, but not HF, was found to amplify EPCs count, this may be related to the sample size, since no interaction effect was observed. Another confounding factor might also be the distribution of sedated and awake patients in the NMES protocol subgroups, resulting in differences related to current tolerance and evoked muscle contraction. In a previous study of our group employing similar NMES protocols, both currents were equally effective in improving thenar oxygen consumption rate, endothelial reactivity and vascular reserve as well as oxygen consumption, demand and supply at the stimulated muscle, measures of systemic and local microcirculation, respectively. These improvements were well correlated to the strength of contraction [16]. Interestingly in another study, oxygen consumption in the biceps brachii during isometric contraction—which could be considered to reflect the magnitude of hypoxic stimuli of the working muscle—increased in proportion to the force developed [39]. In this study, although muscle strength contraction was not systematically recorded, some patients were hardly responded to NMES (no contraction at all or just palpable contraction), as previously observed [40]; however, all patients, ‘responders’ and ‘non-responders’, were included in the analysis, which, in turn, might be related to the marked variability observed among patients. The optimal NMES characteristics to apply in ICU patients are still under investigation [8]. Future studies should further explore the role of NMES to mobilize progenitor cells in relation to strength contraction of the stimulated muscle.

Although ICU patients most to benefit from NMES application have not yet clearly determined, septic patients are definitely a target group of interest. Sepsis induces endothelial and microcirculation dysfunction and is a risk factor for multi-organ failure and ICU-acquired weakness [1, 41]. Endothelial restoration capacity is impaired in sepsis, and circulating EPCs have been suggested to inversely associate with SOFA score and organ dysfunction [42]. Recently, exogenously administered EPCs in septic mice increased anti-inflammatory mediators, attenuated liver and kidney injury, augmented markers of endothelial cell function/inflammation and EPCs recruitment, and improved survival [43]. In this study, both SOFA-based severity subgroups increased EPCs, likely implying that NMES has the potential to mobilize progenitor cells in septic patients irrespective of severity status; however, the clinical implications of this finding need to be explored.

In this study, small—although significant—increases in heart rate, respiratory rate, creatine phosphokinase and lactate were also observed due to NMES application. Interestingly, progenitor cells mobilization after acute exercise was recently related to creatine phosphokinase as a marker of ‘muscle damage’; whether the increase seen in this study might have a role, remains to be elucidated [12]. Overall, these increases, seemingly having not any clinical significance for ICU patients, are rather reflective of a systemic effect of NMES, in line with previous findings from our group [11, 16]. The absence of any clinically significant side effects in terms of cardiac/hemodynamic derangements and ‘muscle damage’ further emphasizes on the NMES role as a safe and well-tolerated intervention in critically ill patients.

On the whole, our findings provide evidence that NMES mobilizes EPCs in ICU patients, measures of the endothelial restoration potential. Increased mobilization of EPCs was approached in terms of counts elevation rather than functional improvement; since increased EPCs counts do not necessarily reflect elevated function, future studies should also address NMES efficacy to affect functional aspects of these cells categories. Accumulating evidence also supports the significance of NMES concerning prevention of ICU-acquired weakness, as well as its potential role in the prevention of thromboembolism and pressure ulcers, comorbidities of critical illness related to disturbed endothelial function. The relation of NMES-induced EPCs mobilization to prevention of these comorbidities warrants further investigation.

A limitation of the study was the small sample size of the patients included; comparisons between or within subgroups were, in some instances, underpowered to demonstrate differences in progenitor cells alterations. In addition, strength contraction and current intensities were not systematically recorded, which could possibly allow for further insight into the potential mechanisms.
of EPCs mobilization; however, by design, current intensities applied—optimally aiming at full muscle contraction—were the maximal tolerated by non-sedated and sedated patients, implying maximum applicable contraction in each case.

Conclusion
NMES acutely mobilized EPCs in severe ICU patients. These effects were not dependent on NMES protocol or sepsis severity status, while they were observed to relate to corticosteroids administration. These later findings the NMES-induced mechanisms of improved EPCs mobilization and their clinical consequences warrant further investigation.

Abbreviations
EPCs: endothelial progenitor cells; CHF: chronic heart failure; NMES: neuromuscular electrical stimulation; HF: high-frequency protocol; MF: medium-frequency protocol; SD: standard deviation; APACHE: acute physiology and chronic health evaluation; SOFA: sequential organ failure assessment.

Authors’ contributions
CS carried out the experiments, participated in the design of the study, clinical assessment of patients, acquisition, analysis and interpretation of the data and drafted the manuscript. CR helped with interpretation of the data and revised critically the manuscript. EA participated in clinical assessment of the patients, experiments and data acquisition and revised the manuscript. GM applied NMES and performed flow cytometry analyses. KP consulted and participated in flow cytometry analyses and revised the manuscript. CR participated in clinical assessment of the patients, experiments and data acquisition and revised the manuscript. SN conceived of the study and its design, coordinated the study, revised critically the manuscript and gave final approval. All authors read and approved the final manuscript.

Author details
1 1st Critical Care Department, Evangelismos General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
2 Immunology and Histocompatibility Department, Evangelismos General Hospital, Athens, Greece.
3 Critical Care Unit, Guys and St Thomas Hospital, Westminster Bridge Road, London SE1 7EH, UK.

Acknowledgements
This study was supported by the Special Account for Research Grants, National and Kapodistrian University of Athens. The authors also acknowledge the contribution of individual donations.

Competing interests
The authors declare that they have no competing interests.

Received: 24 November 2015 Accepted: 29 February 2016
Published online: 11 March 2016

References
1. van Iersel SH, Jorens PG, Van Craenenbroeck EM, Conraads VM. The endothelium, a protagonist in the pathophysiology of critical illness: focus on cellular markers. Biomed Res Int. 2014;2014:985813.
2. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003;348:593–600.
3. Yang Z, Wang JM, Chen L, Luo CF, Tang AL, Tao J. Acute exercise-induced nitric oxide production contributes to upregulation of circulating endothelial progenitor cells in healthy subjects. J Hum Hypertens. 2007;21:452–60.
4. Heiss C, Schanz A, Amabile N, Jahn S, Chen Q, Wong ML, Rassaf T, Heinen Y, Cortese-Krott M, Grossman W, Vehgiazian Y, Springer ML. Nitric oxide synthase expression and functional response to nitric oxide are both important modulators of circulating angiogenic cell response to angiogenic stimuli. Arteioscler Thromb Vasc Biol. 2010;30:2212–8.
5. Van Craenenbroeck EM, Beekers PJ, Possemiers NM, Wynts K, Frederix G, Hoymans VY, Wynts F, Paelinck BP, Vrints CJ, Conraads VM. Exercise acutely reverses dysfunction of circulating angiogenic cells in chronic heart failure. Eur Heart J. 2010;31:1924–34.
6. Ribeiro F, Ribeiro IP, Alves AJ, do Ceu Monteiro M, Oliveira NL, Oliveira J, Amado F, Remiao F, Duarte IA. Effects of exercise training on endothelial progenitor cells in cardiovascular disease: a systematic review. Am J Phys Med Rehabil. 2013;92:1020–30.
7. Gerovasili V, Stefanidis K, Vitziotios I, Karatzanos E, Politis P, Koroneos A, Chatzimichail A, Routsi C, Roussos C, Nanas S. Electrical muscle stimulation preserves the muscle mass of critically ill patients: a randomized study. Crit Care. 2009;13:R61.
8. Maffioletti NA, Roig M, Karatzanos E, Nanas S. Neuromuscular electrical stimulation for preventing skeletal-muscle weakness and wasting in critically ill patients: a systematic review. BMC Med. 2013;11:137.
9. Routsi C, Gerovasili V, Vasilieades I, Karatzanos E, Pitsolis T, Tripodaki E, Markaki V, Zervakis D, Nanas S. Electrical muscle stimulation prevents critical illness polyneuromyopathy: a randomized parallel intervention trial. Crit Care. 2010;14:R74.
10. Williams N, Flynn M. A review of the efficacy of neuromuscular electrical stimulation in critically ill patients. Physiother Theory Pract. 2014;30:6–11.
11. Gerovasili V, Tripodaki E, Karatzanos E, Pitsolis T, Markaki V, Zervakis D, Routsi C, Roussos C, Nanas S. Short-term systemic effect of electrical muscle stimulation in critically ill patients. Chest. 2009;136:1249–56.
12. Kruger K, Pilat C, Schild M, Lindner N, Fech T, Maders K, Moorin FC. Progenitor cell mobilization after exercise is related to systemic levels of G-CSF and muscle damage. Scand J Med Sci Sports. 2015;25:e283–91.
13. Ross MD, Wekesa AL, Phelan JP, Harrison M. Resistance exercise increases endothelial progenitor cells and angiogenic factors. Med Sci Sports Exerc. 2014;46:16–23.
14. Van Craenenbroeck EM, Vrints CJ, Haine SE, Vermeulen K, Goovaerts I, Van Tendeloo VF, Hoymans VY, Conraads VM. A maximal exercise bout increases the number of circulating CD34+/AKDR+/endothelial progenitor cells in healthy subjects. Relation with lipid profile. J Appl Physiol. 2008;104:1006–13.
15. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864–74.
16. Angelopoulos E, Karatzanos E, Dimopoulos S, Mitsiou G, Stefanou C, Patsaki I, Kotanidou A, Routsi C, Petrikikos G, Nanas S. Acute microcirculatory effects of medium frequency versus high frequency neuromuscular electrical stimulation in critically ill patients—a pilot study. Ann Intensive Care. 2013;3:39.
17. Duda DG, Cohen KS, Scadden DT, Jain RK. A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. Nat Protoc. 2007;2:805–10.
18. Fadini GP, Losordo D, Dimmeler S. Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circ Res. 2012;110:264–37.
19. Corral L, Conde L, Guillamo E, Blai J, Juncadella M, Javiera C, Visco G, Ventura JL. Circulating progenitor cells during exercise, muscle electro-stimulation and intermittent hypobaric hypoxia in patients with traumatic brain injury: a pilot study. NeuroRehabilitation. 2014;35:763–9.
20. Corral L, Javerie C, Blai J, Visco G, Ricart A, Ventura JL. Combined intermittent hypobaric hypoxia and muscle electro-stimulation: A method to increase circulating progenitor cell concentration? J Transl Med. 2014;12:174.
21. Hirose T, Shozaki T, Shimizu K, Mouri T, Noguchi K, Ohnishi M, Shimazu T. The effect of electrical muscle stimulation on the prevention of disuse muscle atrophy in patients with consciousness disturbance in the intensive care unit. J Crit Care. 2013;28:336.e1–7.

22. Broderick BJ, Breathnach O, Condon F, Masterson E, Olaghiin G. Haemodynamic performance of neuromuscular electrical stimulation (NMES) during recovery from total hip arthroplasty. J Orthop Surg Res. 2013;8:3.

23. Griffin M, Nicolaides AN, Bond D, Geroulakos G, Kolodki E. The efficacy of a new stimulation technology to increase venous flow and prevent venous stasis. Eur J Vasc Endovasc Surg. 2010;40:676–71.

24. Hermans G, De Jonghe B, Bruyninckx F, Van den Berghe G. Interventions to prevent critical illness polyneuropathy and critical illness myopathy. Cochrane Database Syst Rev. 2014;1:CD011832.

25. Karatzanos E, Gerovasili V, Zervakis D, Tripodaki ES, Apostolou K, Vasileiadis I, Papadopoulos E, Mitsos G, Tsipouloi D, Rontsi C, Nanas S. Electrical muscle stimulation: an effective form of exercise and early mobilization to preserve muscle strength in critically ill patients. Crit Care Res Pract. 2012;2012:847257.

26. Kawasaki L, Mushahwar VK, Ho C, Dukelow SP, Chan LL, Chan KM. The mechanisms and evidence of efficacy of electrical stimulation for healing of pressure ulcer: a systematic review. Wound Repair Regen. 2014;22:161–73.

27. Van Craenenbroeck EM, Bruyndonckx L, Van Berckelaer C, Hoymans VV, Wints CJ, Conraads VM. The effect of acute exercise on endothelial progenitor cells is attenuated in chronic heart failure. Eur J Appl Physiol. 2011;111:2375–9.

28. Tao J, Yang Z, Wang JM, Tu C, Pan SR. Effects of fluid shear stress on eNOS mRNA expression and NO production in human endothelial progenitor cells. Cardiology. 2006;106:82–8.

29. Sandri M, Adams V, Gielen S, Linke A, Krankel N, Lenz D, Erbs S, Scheinert D, Mobius-Winkler S, Hambrecht R. Effects of exercise and ischemia on mobilization and functional activation of blood-derived progenitor cells in patients with ischemic syndromes: results of 3 randomized studies. Circulation. 2005;111:3391–9.

30. Wan C, Li J, Yang C, Hu D, Bi S. Dynamics of endogenous endothelial progenitor cells homing modulated by physiological ischemia training. J Rehabil Med. 2015;47:87–93.

31. Sandri M, Beck EB, Adams V, Gielen S, Lenk K, Hollriegel R, Mangner N, Linke A, Erbs S, Mobius-Winkler S, Scheinert D, Hambrecht R, Schulz R. Maximal exercise, limb ischemia, and endothelial progenitor cells. Eur J Cardiovasc Prev Rehabil. 2011;18:55–64.

32. Muthalib M, Jubeau M, Millet GY, Maffulli NA, Nosaka K. Comparison between electrically evoked and voluntary isometric contractions for biceps brachii muscle oxidative metabolism using near-infrared spectroscopy. Eur J Appl Physiol. 2009;107:235–41.

33. Chen C, Yang S, Feng Y, Wu X, Chen D, Yu Q, Wang X, Li L, Chen J. Impairment of two types of circulating endothelial progenitor cells in patients with glucocorticoid-induced avascular osteonecrosis of the femoral head. Joint Bone Spine. 2013;80:70–6.

34. Patschan S, Patschan D, Polusluk M, Henze E, Scholze J, Muller GA. Endothelial progenitor cells in systemic lupus erythematosus. J Nephrol. 2013;26:1065–72.

35. Jodon de Villeroche V, Avouac J, Ponceau A, Ruiz B, Kahan A, Boileau C, Uzan G, Allanore Y. Enhanced late-outgrowth circulating endothelial progenitor cell levels in rheumatoid arthritis and correlation with disease activity. Arthritis Res Ther. 2010;12:R27.

36. Grisar J, Aketah D, Steiner CW, Kapral T, Steiner S, Saemann M, Schwarzer I, Buranyi B, Steiner G, Smolen JS. Endothelial progenitor cells in active rheumatoid arthritis: effects of tumour necrosis factor and glucocorticoid therapy. Ann Rheum Dis. 2007;66:1284–8.

37. Pirro M, Bocci EB, Di Filippo F, Sciliarci G, Manninno MR, Bagaglia F, Gerli R, Manninno E. Imbalance between endothelial injury and repair in patients with polymyalgia rheumatica: improvement with corticosteroid treatment. J Intern Med. 2012;272:177–84.

38. Lee PY, Li Y, Richards HB, Chan FS, Zhuang H, Narain S, Bufilovski EJ, Sobel ES, Reeves WH, Segal MS. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum. 2007;56:3759–69.

39. Cettolo V, Ferrari M, Biasini V, Quaresima V, Vastus lateralis O2 desaturation for endothelial progenitor cell depletion and endothelial dysfunction in critical illness. Arthritis Rheum. 2007;56:1284–8.

40. Segers J, Hermans G, Bruyninckx F, Meyfroidt G, Langer D, Gosselin R. Feasibility of neovascular muscle electrical stimulation in critically ill patients. J Crit Care. 2014;29:1082–8.

41. Nanas S, Kritikos K, Angelopoulos E, Safakia A, Tsikriki S, Poriasi M, Kanalouptsi D, Kontogeorgi M, Pratikaki M, Zervakis D, Rontsi C, Roussos C. Predisposing factors for critical illness polyneuropathy in multi- disciplinary intensive care unit. Acta Neurol Scand. 2008;118:175–81.

42. Cribbs SK, Sutcliffe DJ, Taylor WR, Rojas M, Easley KA, Tang L, Brigham KL, Martin GS. Endothelial progenitor cells inversely associate with organ dysfunction in sepsis. Intensive Care Med. 2012;38:429–36.

43. Fan H, Goodwin AJ, Chang E, Zingarelli B, Borg K, Guan S, Halushka PV, Cook JA. Endothelial progenitor cells and a stromal cell-derived factor-1alpha analogue synergistically improve survival in sepsis. Am J Respir Crit Care Med. 2014;189:1509–19.